By: Nick Mulcahy From: medscape.com The US Food and Drug Administration (FDA) today granted accelerated approval to brexucabtagene autoleucel (Tecartus, Kite Pharma), the first approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The new agent is the second approved CAR T cell product developed by Kite and follows …
-
-
Peace for a Breast Cancer Survivor
-
What Would Motivate a Person to Action After a Breast Cancer Diagnosis
-
What’s on the Outside Doesn’t Really Matter to Many Breast Cancer Survivors
-
From a Breast Cancer Survivor: A Message to Telephone and Telemarketer Solicitors
-
Love After a Breast Cancer Diagnosis
